Endovascular Engineering today announced the closing of a $15 million Series A1 financing co-led by Santé Ventures and Cordis.
The Menlo Park, California–based startup is also called E2. It’s focused on developing advanced mechanical thrombectomy technology.
“With the close of this funding, we will continue the journey from concept to clinical use. We are confident our vision of single-pass peripheral thrombectomy procedures will be realized with the introduction of E2’s thrombectomy solution,” said Dr. Luis Savastano, E2’s founder and CSO and an assistant professor of neurosurgery and radiology at the Mayo Clinic in Rochester, Minnesota.
Cordis CEO Shar Matin said the investment is part of the Miami Lakes, Florida–based company’s strategy of “expanding our portfolio with innovative and clinically compelling solutions that respond to unmet needs in cardiovascular health.”
The funding places Cordis in the “vanguard of innovation in venous interventions,” said Duke Rohlen, executive chairperson of Cordis and CEO of the independent Cordis-X accelerator.
